Sun Pharmaceutical Industries announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

''The availability of ILUMYATM is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the U.S. ILUMYATM offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,'' said Abhay Gandhi, Chief Executive Officer, Sun Pharma, North America. ''We understand the importance of patient and physician choice, and are committed to making ILUMYATM among the most cost-effective treatments on the market.''

Shares of the company declined Rs 9.5, or 1.65%, to trade at Rs 566.80. The total volume of shares traded was 105,402 at the BSE (10.12 a.m., Wednesday).